Aspen Technology

aspentech.com

Aspen Technology
AspenTech is a global leader in asset optimization software helping the world’s leading industrial companies run their operations more safely, efficiently and reliably – enabling innovation while reducing waste and impact on the environment.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

NRX PHARMACEUTICALS TO WORK WITH CARDINAL HEALTH TO ENSURE EFFICIENT DISTRIBUTION OF POTENTIAL THERAPIES

NRx Pharmaceuticals | August 26, 2021

news image

NRx Pharmaceuticals announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and Drug Administration (FDA). In May, NRx submitted an application for EUA to the FDA for ZYESAMI™ (aviptadil) for patients suffering from Critical COVID-19 with respiratory failure. "This partnership creates an efficient and highly flexible lo...

Read More

LANTERN PHARMA’S PROPRIETARY A.I. PLATFORM SURPASSES 450 MILLION DATA POINTS ACCELERATING ONCOLOGY DRUG DEVELOPMENT AND DRUG RESPONSE PREDICTION

Lantern Pharma | June 30, 2020

news image

Lantern Pharma, a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and...

Read More

Business Insights

TIKOMED AND IQVIA ANNOUNCE A STRATEGIC COLLABORATION FOR THE DEVELOPMENT OF TIKOMED'S LEAD DRUG PLATFORM CANDIDATE ILB®

Tikomed | May 09, 2022

news image

Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration will support TikoMed's clinical development, regulatory and commercial strategies. IQVIA brings together deep therapeutic experti...

Read More

CPD and Learning

POSTERA AND NEUROLUCENT PARTNERS ON IDENTIFYING SMALL-MOLECULE THERAPEUTICS FOR ALZHEIMER'S DISEASE

PostEra | November 27, 2020

news image

PostEra, a biotechnology organization offering restorative science fueled by AI, today reported a joint effort with NeuroLucent, a Chicago-put together organization centered with respect to creating novel medicines for Alzheimer's sickness and different dementias. The disappointment of late-stage clinical preliminaries to reveal viable treatments for Alzheimer's illness has underscored the need to investigate novel helpful methodologies. NeuroLucent is creating novel littl...

Read More
news image

Pharmacy Market

NRX PHARMACEUTICALS TO WORK WITH CARDINAL HEALTH TO ENSURE EFFICIENT DISTRIBUTION OF POTENTIAL THERAPIES

NRx Pharmaceuticals | August 26, 2021

NRx Pharmaceuticals announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and Drug Administration (FDA). In May, NRx submitted an application for EUA to the FDA for ZYESAMI™ (aviptadil) for patients suffering from Critical COVID-19 with respiratory failure. "This partnership creates an efficient and highly flexible lo...

Read More
news image

LANTERN PHARMA’S PROPRIETARY A.I. PLATFORM SURPASSES 450 MILLION DATA POINTS ACCELERATING ONCOLOGY DRUG DEVELOPMENT AND DRUG RESPONSE PREDICTION

Lantern Pharma | June 30, 2020

Lantern Pharma, a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and...

Read More
news image

Business Insights

TIKOMED AND IQVIA ANNOUNCE A STRATEGIC COLLABORATION FOR THE DEVELOPMENT OF TIKOMED'S LEAD DRUG PLATFORM CANDIDATE ILB®

Tikomed | May 09, 2022

Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration will support TikoMed's clinical development, regulatory and commercial strategies. IQVIA brings together deep therapeutic experti...

Read More
news image

CPD and Learning

POSTERA AND NEUROLUCENT PARTNERS ON IDENTIFYING SMALL-MOLECULE THERAPEUTICS FOR ALZHEIMER'S DISEASE

PostEra | November 27, 2020

PostEra, a biotechnology organization offering restorative science fueled by AI, today reported a joint effort with NeuroLucent, a Chicago-put together organization centered with respect to creating novel medicines for Alzheimer's sickness and different dementias. The disappointment of late-stage clinical preliminaries to reveal viable treatments for Alzheimer's illness has underscored the need to investigate novel helpful methodologies. NeuroLucent is creating novel littl...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us